Latest Articles about OREX

ARNA Sheds Light on Belviq Launch - Analyst Blog

Zacks Equity Research — Fri, 10 May 2013 00:24:33 Z

Arena Pharmaceuticals Inc. ( ARNA ) recently announced that the US Drug Enforcement Administration (DEA) has assigned its obesity drug Belviq into Schedule IV of the Controlled Substances

Expanded Access for VIVUS' Qsymia - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 03:10:09 Z

VIVUS, Inc. ( VVUS ) recently announced that the amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) of its obesity drug, Qsymia (phentermine and topiramate

ARNA/Eisai's Belviq Filed in Mexico - Analyst Blog

Zacks Equity Research — Thu, 04 Apr 2013 00:19:58 Z

Arena Pharmaceuticals, Inc. ( ARNA ) recently announced that Eisai Laboratories S. de R.L. de C.V, a subsidiary of Eisai Inc., has submitted a marketing authorization application (MAA) for

Vivus Opts for Royalty Financing - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 03:21:59 Z

Vivus, Inc. ( VVUS ) recently announced that it has entered into an agreement with a Pharmakon Advisors managed investment fund for a $110 million non-equity financing. Vivus will initially

Company News for March 15, 2013 - Corporate Summary

Zacks Equity Research — Fri, 15 Mar 2013 17:44:37 Z

• Vera Bradley, Inc. (NASDAQ: VRA ) posted fourth quarter earnings per share of $0.62, surpassing the Zacks Consensus Estimate of $0.57 • Orexigen

Loss at OREX Narrower than Expected - Analyst Blog

Mark Vickery — Fri, 15 Mar 2013 01:45:16 Z

Orexigen Therapeutics, Inc. ( OREX ) reported a net loss of 41 cents per share in the fourth quarter of 2012, much wider than the year-ago loss of 9 cents but 4 cents narrower than the

Vivus Reports Wider Loss - Analyst Blog

Zacks Equity Research — Tue, 26 Feb 2013 23:54:01 Z

Vivus Inc. 's ( VVUS ) fourth quarter 2012 loss of 56 cents per share was wider than the Zacks Consensus Estimate of a loss of 44 cents per share and the year-ago loss of 14 cents per

CHMP Still Negative on Vivus' Qsiva - Analyst Blog

Zacks Equity Research — Sat, 23 Feb 2013 02:15:01 Z

Vivus, Inc. ( VVUS ) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) re-examined and confirmed its decision about

Update on Orexigen's Contrave - Analyst Blog

Zacks Equity Research — Fri, 11 Jan 2013 03:51:01 Z

Orexigen Therapeutics, Inc. ( OREX ) recently provided an update on its obesity candidate, Contrave. The company, which had received a complete response letter (CRL) from the US Food and

How Many Stocks in this Industry Could Tumble Into Bankruptcy?

David Sterman — Wed, 21 Nov 2012 23:00:00 Z

Declaring bankruptcy has one clear benefit. It allows management torestructure a business without worrying about near-term debts coming due. Airline carrier AMR, for example, is fixing the holes

Vivus Misses 3Q Estimates - Analyst Blog

Zacks Equity Research — Fri, 09 Nov 2012 01:00:01 Z

Vivus Inc. ( VVUS ) reported a loss of 40 cents per share in the third quarter of 2012, wider than the Zacks Consensus Estimate of a loss of 33 cents and the year-ago loss of 10 cents per

CHMP Negative on Vivus' Qsiva - Analyst Blog

Zacks Equity Research — Mon, 22 Oct 2012 22:30:38 Z

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend the approval of Vivus Inc. 's ( VVUS ) weight-loss drug, Qsiva.

The right data is key to spotting trends

David Russell — Fri, 21 Sep 2012 18:34:03 Z

One of the reasons that we created researchLAB was to identify and track companies like the makers of obesity drugs : Arena Pharmaceuticals (ARNA), Orexigen Therapeutics (OREX), and Vivus

Vivus Launches Obesity Drug Qsymia - Analyst Blog

Zacks Equity Research — Fri, 21 Sep 2012 02:22:01 Z

Vivus Inc. ( VVUS ) recently announced the launch of its obesity drug, Qsymia, in the US following the US Food and Drug Administration's (FDA) approval on July 17, 2012. Qsymia is the first

Buy or Sell? Wednesday's Winners: GWRE, OREX

David Sterman — Wed, 05 Sep 2012 17:30:00 Z

Among the biggest winners in Wednesday's early trading are Guidewire Software (Nasdaq: GWRE) and Orexigen Therapeutics (Nasdaq: OREX) . While the 2012IPO market will always be remembered